Company: BNBX
Filing Date: 2025-04-04
Form Type: PRE 14A
Source: 0001104659-25-032262
Chunk: 44

Company: BNB PLUS CORP.
Filing Date: 2025-04-04
Form: PRE 14A
Chunk 44
---
 component of designing competitive compensation packages necessary for retaining key talent and directors in a competitive marketplace, specifically in light of our negative operating cashflows and historical operating losses, (v) our strategic growth plans, and (vi) the interests of our stockholders. The Compensation Committee of our Board monitors our equity award process to ensure that we maximize stockholder value by granting only the appropriate number of equity awards necessary to attract, reward and retain employees and directors. In addition, the Current Plan includes, and the Amended Plan will include, provisions designed to be less dilutive to stockholders. As described further below, the Current Plan does not, and the Amended Plan will not, contain an “evergreen” provision, so the number of shares available for issuance under the Current Plan does not automatically increase each year and likewise will not automatically increase under the Amended Plan. The below table summarizes grants under our Current Plan for the last three fiscal years.

| ​    | ​ | ​ | OptionsGranted |   |       |   | ​ | ​ | RSUsGranted |   |     |   | ​ | ​ | Weighted AverageCommon SharesOutstanding EachYear |   |        |   | ​ |
| 2022 | ​ | ​ | ​              | ​ |   588 | ​ | ​ | ​ | ​           | ​ |   — | ​ | ​ | ​ | ​                                                 | ​ |  8,968 | ​ | ​ |
| 2023 | ​ | ​ | ​              | ​ | 1,003 | ​ | ​ | ​ | ​           | ​ | 283 | ​ | ​ | ​ | ​                                                 | ​ | 13,075 | ​ | ​ |
| 2024 | ​ | ​ | ​              | ​ |     — | ​ | ​ | ​ | ​           | ​ |   — | ​ | ​ | ​ | ​                                                 | ​ | 79,321 | ​ | ​ |

28

TABLE OF CONTENTS Maintaining our current equity compensation program is particularly critical at this time when competition for quality personnel is intense in the highly competitive biotechnology marketplace in which we operate, and our ability to successfully execute, compete and deliver value to stockholders could be significantly negatively impacted if we cannot maintain our current equity award practices in support of retaining and attracting key talent. If we are limited in our ability to grant desired equity awards to our employees and other eligible individuals, we may not be able to compete for or retain key talent, and/or we may